



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	J. Komorowski et al.)	Group Art Unit 1651
Appl. No.	:	10/001322)	I hereby certify that this correspondence and all marked attachments are being
Filed	:	October 31, 2001)	deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327,
For		METHODS AND)	Arlington, VA 22202, on
		COMPOSITIONS FOR THE)	January 22, 2003
		IMPROVEMENT OF INSULIN)	(Date)
		SENSITIVITY, REDUCTION).	The second of the second
		OF HYPERGLYCEMIA, AND)	Mallary K. de Merlier, Reg. No. 51,609
		REDUCTION OF)	
		HYPERCHOLESTEROLEMIA)	RECE
		WITH CHROMIUM)	RECEIVED
		COMPLEXES AND ALPHA)	
		LIPOIC ACID)	TEB 9 6 7000
Examiner	:	Patten, Patricia A.)	FEB 9 6 2000 TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

United States Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Sir:

In response to the Office Action mailed on September 23, 2002 (Paper No. 5), please amend the above-referenced patent application as follows:

IN THE CLAIMS:

Please CANCEL claims 10-26 without prejudice to further prosecution.

REMARKS

Applicants acknowledge receipt of the Office Action mailed on September 23, 2002 (Paper No. 5). Claims 1-9 are pending in the application; Claims 10-26 have been cancelled without prejudice to further prosecution, as being drawn to non-elected subject matter. To summarize, the PTO rejected Claims 1-9 under 35 U.S.C. §102(e) as being anticipated by Carthron (U.S. Patent No. 6,277,842). Claims 1-9 were likewise rejected under 35 U.S.C.